Syndax Pharmaceuticals Inc - Director's Dealing 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Syndax Pharmaceuticals Inc (SNDX)
CIK: 0001395937
Period of Report: 2021-09-20

Reporting Person: Metzger Michael A (N/A)

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-09-20	Common Stock	M	31455.00	$7.20	Acquired	49114.00	Direct
2021-09-20	Common Stock	S	31455.00	$19.2353	Disposed	17659.00	Direct
2021-09-21	Common Stock	M	4808.00	$7.20	Acquired	22467.00	Direct
2021-09-21	Common Stock	S	4808.00	$19.1573	Disposed	17659.00	Direct
2021-09-22	Common Stock	M	300.00	$7.20	Acquired	17959.00	Direct
2021-09-22	Common Stock	S	300.00	$19.02	Disposed	17659.00	Direct

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-09-20	Stock Options (Right to buy)	$7.20	M	31455.00	Disposed	2025-06-01	Common Stock (31455.00)	Direct
2021-09-21	Stock Options (Right to buy)	$7.20	M	4808.00	Disposed	2025-06-01	Common Stock (4808.00)	Direct
2021-09-22	Stock Options (Right to buy)	$7.20	M	300.00	Disposed	2025-06-01	Common Stock (300.00)	Direct

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person.

F2: The sale price ranged from $19.00 to $19.92

F3: The sale prices ranged from $19.02 to $19.31

F4: The sale prices ranged from $19.00 to $19.06

F5: This option is fully vested.